Skip to main content
. 2019 Feb 28;14(2):e0212832. doi: 10.1371/journal.pone.0212832

Fig 2. Incremental per-member per-month (MYR) cost impact after increasing uptake of renin-angiotensin system inhibitor drugs.

Fig 2